Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
RasCal Therapeutics, Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Centre hospitalier de l'Université de Montréal (CHUM)
Seagen Inc.
Boehringer Ingelheim
Frontier Medicines Corporation
Chinese University of Hong Kong
City of Hope Medical Center
National Cancer Institute (NCI)
AstraZeneca
Cairo University
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University Hospital, Tours
bioAffinity Technologies Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Gilead Sciences
University of California, San Francisco
Bristol-Myers Squibb
Filamon LTD
AstraZeneca
National Cancer Institute (NCI)
Cairo University
Bristol-Myers Squibb
Bristol-Myers Squibb
The First Affiliated Hospital with Nanjing Medical University
Pfizer
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
University of Cadiz